- Home
- EXPD vs MRNA Comparison
EXPD vs MRNA Comparison
Compare EXPD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXPD
- MRNA
- Stock Information
- Founded
- EXPD 1979
- MRNA 2010
- Country
- EXPD United States
- MRNA United States
- Employees
- EXPD N/A
- MRNA N/A
- Industry
- EXPD Oil Refining/Marketing
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EXPD Consumer Discretionary
- MRNA Health Care
- Exchange
- EXPD Nasdaq
- MRNA Nasdaq
- Market Cap
- EXPD 15.3B
- MRNA 13.4B
- IPO Year
- EXPD N/A
- MRNA 2018
- Fundamental
- Price
- EXPD $119.80
- MRNA $28.02
- Analyst Decision
- EXPD Sell
- MRNA Hold
- Analyst Count
- EXPD 10
- MRNA 20
- Target Price
- EXPD $114.11
- MRNA $46.24
- AVG Volume (30 Days)
- EXPD 1.3M
- MRNA 8.6M
- Earning Date
- EXPD 08-05-2025
- MRNA 08-01-2025
- Dividend Yield
- EXPD 1.28%
- MRNA N/A
- EPS Growth
- EXPD 31.92
- MRNA N/A
- EPS
- EXPD 6.14
- MRNA N/A
- Revenue
- EXPD $11,273,140,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- EXPD N/A
- MRNA N/A
- Revenue Next Year
- EXPD $1.61
- MRNA $10.04
- P/E Ratio
- EXPD $19.51
- MRNA N/A
- Revenue Growth
- EXPD 23.70
- MRNA N/A
- 52 Week Low
- EXPD $100.47
- MRNA $23.15
- 52 Week High
- EXPD $131.59
- MRNA $91.99
- Technical
- Relative Strength Index (RSI)
- EXPD 57.14
- MRNA 46.33
- Support Level
- EXPD $115.35
- MRNA $25.30
- Resistance Level
- EXPD $122.40
- MRNA $27.08
- Average True Range (ATR)
- EXPD 2.92
- MRNA 1.33
- MACD
- EXPD 0.46
- MRNA -0.31
- Stochastic Oscillator
- EXPD 78.19
- MRNA 32.38
About EXPD Expeditors International of Washington Inc.
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.